122 related articles for article (PubMed ID: 34830178)
1. Cabozantinib Is Effective in Melanoma Brain Metastasis Cell Lines and Affects Key Signaling Pathways.
Mannsåker TA; Hoang T; Aasen SN; Bjørnstad OV; Parajuli H; Sundstrøm T; Thorsen FA
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830178
[TBL] [Abstract][Full Text] [Related]
2. In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.
Daphu I; Horn S; Stieber D; Varughese JK; Spriet E; Dale HA; Skaftnesmo KO; Bjerkvig R; Thorsen F
Int J Mol Sci; 2014 May; 15(5):8773-94. PubMed ID: 24840574
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms.
Scott AJ; Arcaroli JJ; Bagby SM; Yahn R; Huber KM; Serkova NJ; Nguyen A; Kim J; Thorburn A; Vogel J; Quackenbush KS; Capasso A; Schreiber A; Blatchford P; Klauck PJ; Pitts TM; Eckhardt SG; Messersmith WA
Mol Cancer Ther; 2018 Oct; 17(10):2112-2122. PubMed ID: 30026382
[TBL] [Abstract][Full Text] [Related]
4. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
Ruan M; Liu M; Dong Q; Chen L
J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
[TBL] [Abstract][Full Text] [Related]
5. MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme.
Knubel KH; Pernu BM; Sufit A; Nelson S; Pierce AM; Keating AK
Oncotarget; 2014 Mar; 5(5):1338-51. PubMed ID: 24658326
[TBL] [Abstract][Full Text] [Related]
6. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.
Hage C; Rausch V; Giese N; Giese T; Schönsiegel F; Labsch S; Nwaeburu C; Mattern J; Gladkich J; Herr I
Cell Death Dis; 2013 May; 4(5):e627. PubMed ID: 23661005
[TBL] [Abstract][Full Text] [Related]
7. Elucidating the role of the FoxO3a transcription factor in the IGF-1-induced migration and invasion of uveal melanoma cancer cells.
Yan F; Liao R; Farhan M; Wang T; Chen J; Wang Z; Little PJ; Zheng W
Biomed Pharmacother; 2016 Dec; 84():1538-1550. PubMed ID: 27881235
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.
Zhang L; Scorsone K; Woodfield SE; Zage PE
Cancer Chemother Pharmacol; 2015 Nov; 76(5):977-87. PubMed ID: 26407819
[TBL] [Abstract][Full Text] [Related]
9. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.
Yang S; Zhang X; Qu H; Qu B; Yin X; Zhao H
Cancer Gene Ther; 2020 May; 27(5):368-377. PubMed ID: 31182761
[TBL] [Abstract][Full Text] [Related]
11. HDAC Inhibition Enhances the
Faião-Flores F; Emmons MF; Durante MA; Kinose F; Saha B; Fang B; Koomen JM; Chellappan SP; Maria-Engler SS; Rix U; Licht JD; Harbour JW; Smalley KSM
Clin Cancer Res; 2019 Sep; 25(18):5686-5701. PubMed ID: 31227503
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J
Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for 'Off-Target' Effects Not Mediated by c-Met Inhibition.
Reuther C; Heinzle V; Spampatti M; Vlotides G; de Toni E; Spöttl G; Maurer J; Nölting S; Göke B; Auernhammer CJ
Neuroendocrinology; 2016; 103(3-4):383-401. PubMed ID: 26338447
[TBL] [Abstract][Full Text] [Related]
14. CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation.
Wang DD; Chen Y; Chen ZB; Yan FJ; Dai XY; Ying MD; Cao J; Ma J; Luo PH; Han YX; Peng Y; Sun YH; Zhang H; He QJ; Yang B; Zhu H
Mol Cancer Ther; 2016 Dec; 15(12):2916-2925. PubMed ID: 27638856
[TBL] [Abstract][Full Text] [Related]
15. The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma
Nakatani M; Watari H; Mitamura T; Wang L; Hatanaka Y; Hatanaka KC; Honda K; Nomura T; Nishihara H; Tanaka S; Sakuragi N
Anticancer Res; 2017 Nov; 37(11):6125-6132. PubMed ID: 29061793
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway.
Ivanov VN; Hei TK
Oncogene; 2005 Jan; 24(4):616-26. PubMed ID: 15580309
[TBL] [Abstract][Full Text] [Related]
17. Interruption of mitochondrial complex IV activity and cytochrome c expression activated O₂·⁻-mediated cell survival in silibinin-treated human melanoma A375-S2 cells via IGF-1R-PI3K-Akt and IGF-1R-PLC γ-PKC pathways.
Jiang YY; Huang H; Wang HJ; Wu D; Yang R; Tashiro S; Onodera S; Ikejima T
Eur J Pharmacol; 2011 Oct; 668(1-2):78-87. PubMed ID: 21703257
[TBL] [Abstract][Full Text] [Related]
18. MERTK receptor tyrosine kinase is a therapeutic target in melanoma.
Schlegel J; Sambade MJ; Sather S; Moschos SJ; Tan AC; Winges A; DeRyckere D; Carson CC; Trembath DG; Tentler JJ; Eckhardt SG; Kuan PF; Hamilton RL; Duncan LM; Miller CR; Nikolaishvili-Feinberg N; Midkiff BR; Liu J; Zhang W; Yang C; Wang X; Frye SV; Earp HS; Shields JM; Graham DK
J Clin Invest; 2013 May; 123(5):2257-67. PubMed ID: 23585477
[TBL] [Abstract][Full Text] [Related]
19. PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
Niessner H; Schmitz J; Tabatabai G; Schmid AM; Calaminus C; Sinnberg T; Weide B; Eigentler TK; Garbe C; Schittek B; Quintanilla-Fend L; Bender B; Mai M; Praetorius C; Beissert S; Schackert G; Muders MH; Meinhardt M; Baretton GB; Dummer R; Flaherty K; Pichler BJ; Kulms D; Westphal D; Meier F
Clin Cancer Res; 2016 Dec; 22(23):5818-5828. PubMed ID: 27307593
[TBL] [Abstract][Full Text] [Related]
20. Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.
Gebreyohannes YK; Schöffski P; Van Looy T; Wellens J; Vreys L; Cornillie J; Vanleeuw U; Aftab DT; Debiec-Rychter M; Sciot R; Wozniak A
Mol Cancer Ther; 2016 Dec; 15(12):2845-2852. PubMed ID: 27777285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]